Tokyo, April 6 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061139) titled 'Long-term metabolic profiles and treatment intensity during imeglimin therapy in patients with type 2 diabetes: a retrospective observational study' on April 6.
Study Type:
Observational
Primary Sponsor:
Institute - Osaka General Medical Center
Condition:
Condition - type 2 diabetes
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To describe long-term changes in glycemic control and endogenous insulin secretion in patients with type 2 diabetes receiving imeglimin in routine clinical practice.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with type 2 diabetes aged 20 or older who started imeglimin and continued treatment for 12 months or more.
Key exclusion criteria - Cases with type 1 diabetes, pregnant or breastfeeding women, patients with serious acute illnesses, and cases with insufficient follow-up data.
Target Size - 73
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2024 Year 10 Month 28 Day
Date of IRB - 2024 Year 10 Month 28 Day
Anticipated trial start date - 2024 Year 10 Month 28 Day
Last follow-up date - 2026 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069893
Disclaimer: Curated by HT Syndication.
